Skip to content
Subscriber Only

Analyst-Turned-CEO Says His Biotech Stock Is Cheap, Even After a 900% Rally

Tessa Therapeutics Pte. Research At Their IMDB-Co-Lab And The NCCS Lab Facilities
Photographer: Nicky Loh/Bloomberg
Updated on

You’ll have to forgive Viking Therapeutics’s chief executive for slipping into analyst speak when noting his company is trading at a “tremendous discount.”

Brian Lian used to cover biotechnology firms at SunTrust, but the former sell-side analyst has been running Viking for the past six years. So instead of passing judgment and bestowing ratings, he’s getting ready to present pivotal data later this year on the company’s drug candidate for liver disease.